SEORANG PENDERITA HEPATITIS B AKUT BERAT, MUTAN “PRECORE”, GENOTIP C, YANG DITERAPI DENGAN ENTECAVIR MENGALAMI KECURIGAAN SINDROMA GIANOTTI-CROSTI

Hendrata Erry Andisari

doi:10.30649/obj.v6i2.111

Authors

Hendrata Erry Andisari Universitas Hang Tuah

DOI:

https://doi.org/10.30649/obj.v6i2.111

Keywords:

Hepatitis B, Mutant, Genotype C, Entecavir, Gianotti-Crosti

Abstract

Introduction: The clinical course of HBV is very dynamic and difficult to predict, it can survive in the liver without causing clinical symptoms, or transform into a mutant form with clinical manifestations of severe acute hepatitis B (HBA) or fulminant hepatitis.

Case: Patient Mr. AS, 22 years old, came to a private clinic (West Surabaya) on January 22, 2022. Due to yellow eyes, since 1 week before the patient has complained of weakness, lack of appetite, muscle and joint pain, and body aches.

Conclusion: Entecavir therapy in Severe HBA is safe, provides clinical improvement, accompanied by clearing of HBV DNA and rapid anti-HBs seroconversion occurs.

References

Ciupe SM, Ribeiro RM, Nelson PW, and Perelson, AS. Modeling the mechanisms of acute hepatitis B virus infection. J Theor Biol 2007 July 7; 247(1): 23–35

Jindal A, Kumar K, and Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver International 2013; 33(1) :164-175

Thomas G.F, Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response. Gut 1993; 34: 1-3

Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura K, Hikiji K, and Kato M. Long-Term Histologic and Virologic Outcomes of Acute Self-Limited Hepatitis B. Hepatology 2003;37:1172- 1179

Harroch EO, Levy L, and Chetrit EB. Acute hepatitis B or exacerbation of chronic hepatitis B-that is the question. World J Gastroenterol 2008; 14(46): 7133-7137

Heathcote J, Chair (IASL), Elewaut A (WGO), Fedail S (WGO), Gangl A (WHO), Hamid (WGO), Shah M (WGO), Lavanchy D (WHO), Liu W (WGO), Krabshuis K (WGO). Management of acute viral hepatitis. WGO Practice Guidelines Acute viral hepatitis 2003. World Gastroenterology Organisation, 2007: 1- 23

Guirgis BS, Abbas RO, and Azzazy HM Hepatitis B virus genotyping: current methods and clinical implications. International Journal of Infectious Diseases 2010;14: e941–e953

Fung J, Lai CL, Seto WK and Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011; 66: 2715–2725

Choi HJ, Ko SY, Choe WH, Seo YS, Kim JH, Byun, KS, Kim YS, Kim SU, Baik SK, Cheong JY, Kim TY, Kwon OS, Kim JH, Lee CH and Kwon SY. Clinical features of acute viral hepatitis B in Korea: a multi- center study. The Korean Journal of Hepatology 2011;17:307-312

World Health Organization recommended surveillance standard. second edition 1999 : 1-153

Socio GV, Sgrelli A, Tosti A and Baldelli F. Severe Acute Hepatitis B Treated With Entecavir. Mediterr J Hematol Infect Dis 2011; 3 :1-4.

Kumar M,. Sarin SK, Sharma BC. Department of Gastroenterology. Hepatology 2007;46(2):607-608

Lok AS and McMahon BJ. AASLD Practice Guidelines; Chronic Hepatitis B: Update 2009. Hepatology 2009;50(3): 661-662

Maruyama T, Scodel F, Iino S, Koike K, Yasuda K, Peterson D and Milich DR. Distinguishing Between Acute and Symptomatic Chronic Hepatitis B Virus Infection. Gastroenterology 1 9 9 4 ; 1 0 6 : 1 0 0 6 - 1 0 1 5.

Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006;37(3):206-212.

Mastroianni CM, Lichtner M, Citton R, Borgo CD, Rago A, Martini H, Cimino C, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17(34): 3881-3887

Balistreri WF. Precore and Core Promoter Mutations in Hepatitis B Virus Infection. Medscape Gastroenterology 2005;7(2): 1-2

Pan PQ and Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection Int. J. Med. Sci 2005; 2(1):36-40

Kusumoto K, Yatsuhashi H, Nakao R, Hamada R, Fukuda M, Tamada Y, Taura N, Komori A, Daikoku M, Hamasaki K, Nakao K, Ishibashi H, Miyakawa Y, Eguchi Y. Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis

B. Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. Journal of Gastroenterology and Hepatology 2008;23(5):790-793.

Hakami A, Ali A and Hakami A. Effects of Hepatitis B Virus Mutations on its Replication and Liver Disease Severity. The Open Virology Journal 2013; 7: 12-18.

Utama A, Siburian MD, Purwantomo S, Bayu MD, Intan, Kurniasih TS, Gani RA, Achwan WA, Arnelis, Lelosutan SA, Lukito B, Harmono T, Zubir N, Julius, Soemohardjo S, Lesmana LA, Sulaiman A, Tai S. Association of core promoter mutations of hepatitis B virus and viral load is different in HBeAg(+) and HBeAg(-) patients.World J Gastroenterol. 2011; 17(6): 708-716

Zhang D, Ma S, Zhang X, Zhao H, Ding H, Zeng C. Prevalent HBV point mutations and mutation combinations at BCP/preC region and their association with liver disease progression. BMC Infectious Diseases 2010; 10:271.

Alfaresi M, Elkoush A, Alshehhi H, Alzaabi A, and Islam A. Hepatitis B virus genotypes and precore and core mutants in UAE patients. Virology Journal 2010; 7:160

Baumert TF, Thimme R, Weizsäcker FZ. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 82-90.

Chu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF. Precore Mutant of Hepatitis B Virus Prevails in Acute and Chronic Infections in an Area in Which Hepatitis B Is Endemic. Journal of Clinical Microbiology 1996;34(7): 1815-1818.

Whalley SA, Murray JM, Brown D, Webster GJ, Emery VC, Dusheiko GM, and Perelson AS. Kinetics of Acute Hepatitis B Virus Infection in Humans.The Journal of Experimental Medicine 2001;193: 847–853

Lin CL and Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. Journal of Gastroenterology and Hepatology 2011; 26(1): 123–130

Kao JH, Chen PJ, Lai MY, and Chen DS. Genotypes and Clinical Phenotypes of Hepatitis B Virus in Patients with Chronic Hepatitis B Virus Infection. Journal Of Clinical Microbiology 2002;40: 1207–1209

Shia M, Zhanga Y, Zhangb J, Liua W, Xinga L. Hepatitis B virus genotypes, precore mutations, and basal core promoter mutations in HBV- infected Chinese patients with persistently normal alanine aminotransferase and low serum HBV-DNA levels. Braz J Infect Dis 2012;16(1):52-56

Girke J, Wedemeyer H, Wiegand P, Manns MP, Tillmann. HL. Acute hepatitis B: is antiviral therapy necessary? Two illustrative case reports. Dtsch med Wochenschr 2008; 133(22): 1178-1182

Ganem D, and Prince AM. Hepatitis B Virus Infection; Natural History and Clinical Consequences.N Engl J Med 2004;350:1118-29

Lisotti A, Azzaroli F, Buonfiglioli F, Montagnani M, Alessandrelli F, Mazzella G. Lamivudine treatment for severe acute HBV hepatitis. Int. J. Med. Sci 2008;5(6):309-312

Reshef R, Sbeit W, Kaspa RT. Lamivudine in the Treatment of Acute Hepatitis B. The New England Journal of Medicine 2000;343(15):1123- 1124

Weiss HS, Ari ZB, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, Safadi R, Lurie Y, Rosner G, Kaspa RT, Reshef R. Lamivudine treatment for

acute severe hepatitis B: a pilot study. Liver International 2004;24:547- 551

Kumar BM, Satapathy S, Monga RK. Das S. Hissar C. Pande BC. Sharma, and Sarin SK. A Randomized Controlled Trial of Lamivudine to Treat Acute Hepatitis. Hepatology 2007;45:97-101

Torii N, Hasegawa K, Ogawa M, Hashimo E, Hayashi N. Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002 Sep;24(1):34

Liang TJ. Hepatitis B: The Virus and Disease. Hepatology 2009; 49(5): S13–S21

Miguelez M, Bueno J, Laynez P. Polyarteritis nodosa associated with precore mutant hepatitis B virus infection. New Engl J Med 2001;334 : 173-174

Tillmann HL, Zachou K and Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver International 2012;32(4) :544-553